1. What Is the ALS Market?
The ALS Market covers the treatments used to manage the amyotrophic lateral sclerosis that destroys the upper and lower motor neurons. The disease causes the progressive weakness, the respiratory failure, and the death that occurs within 3 to 5 years of symptom onset in the majority of ALS patients. The patients without the genetic mutation or the exceptional long survival phenotype follow this trajectory. ALS drug development faces the mechanistic heterogeneity that the clinical presentation of the motor neuron degeneration shares across the diverse genetic and sporadic aetiologies. The aetiologies include the SOD1 mutation, the C9orf72 hexanucleotide repeat expansion, the TDP-43 pathology, and the FUS mutation. Each may require the specific targeted therapy that the one-size-fits-all approach that the previous ALS drugs riluzole and edaravone used does not discriminate across the heterogeneous aetiologies. The ALS market is being advanced by the tofersen antisense oligonucleotide that silences the SOD1 mRNA. The tofersen delays the onset of the SOD1-mutated ALS in the presymptomatic population and slows the decline in the symptomatic SOD1 ALS patients. The precision medicine approach demonstrates that the genetic cause determines the specific treatment that the molecular mechanism targets.
2. ALS Market Size & Forecast
3. Emerging Technologies
- Tofersen Qalsody SOD1-targeting antisense oligonucleotide ATLAS trial demonstrated the 55 percent lower risk of developing ALS symptoms in the presymptomatic SOD1-mutated individuals who received the treatment before symptom onset. This represents the first ALS prevention trial success. The neurofilament light chain plasma biomarker monitored the neurodegeneration that tofersen reduced before the clinical symptoms that the primary endpoint measured.
- Riluzole glutamate antagonist reduces the excitotoxic neuronal death from the glutamate receptor hyperactivation. The drug has provided the modest 2 to 3-month survival extension that the 30-year-old approval demonstrated. Riluzole was the only licensed ALS treatment before the edaravone approval and the more recently approved Relyvrio and tofersen added to the limited treatment options.
- Relyvrio sodium phenylbutyrate and taurursodiol combination reduces the endoplasmic reticulum stress and the mitochondrial dysfunction that ALS neurons experience. The combination demonstrated 25 percent slower ALSFRS-R functional decline at 24 weeks in the CENTAUR trial. The FDA granted the accelerated approval based on the functional outcome benefit that the regulatory agency accepted as reasonably likely to predict the survival benefit that the Phase III confirmatory trial was required to demonstrate.
- Gene therapy approaches for the ALS subtypes include the SOD1 antisense approach expanded to the intrathecal and intravenous delivery that the RNA-targeting approach achieves. The C9orf72 repeat expansion antisense oligonucleotide targets the toxic RNA that the hexanucleotide repeat expansion in the intronic sequence creates. The approach targets the toxic RNA rather than the protein that the repeat encodes.
Comparable technologies are influencing adjacent market segments in similar ways. Read more in our Rare Disease Drug Market.
4. Key Market Opportunity
Material revenue potential in the ALS market is C9orf72-targeted therapy development, where successful clinical validation of an ASO or RNA interference approach to the most common genetic ALS cause would substantially expand precision ALS therapy. Companies advancing C9orf72 programmes capture a major precision genetic ALS opportunity. Adjacent demand centers on sporadic ALS therapy development. As C9orf72 programmes advance and sporadic ALS approaches mature, the addressable opportunity is expanding from established symptomatic therapy and the small SOD1 precision population toward broader genetic and sporadic ALS treatment.
5. Top Companies in the ALS Market
The following organisations hold leading positions in the ALS Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Mitsubishi Tanabe Pharma
- Biogen
- Ionis Pharmaceuticals
- Amylyx Pharmaceuticals
- Sanofi
- PTC Therapeutics
- Denali Therapeutics
- Cytokinetics
- BrainStorm Cell Therapeutics
6. Market Segmentation
The ALS Market is analysed across 3 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Drug Class | Riluzole Edaravone ASO Tofersen AMX0035 Pipeline |
| By Genetic Subtype | SOD1 C9orf72 FUS Sporadic |
| By Geography | North America The U.S. Canada Europe The UK Germany France Italy Spain Denmark Netherlands Finland Sweden Norway Russia Austria Poland Rest of Europe Asia Pacific China Japan India South Korea Australia Indonesia Vietnam Philippines Singapore Taiwan Thailand Rest of Asia Pacific Latin America Brazil Mexico Argentina Rest of South America Middle East and Africa GCC Countries Israel South Africa Rest of Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the ALS Market trajectory over the forecast period:
Tofersen ATLAS Presymptomatic SOD1 ALS 55 Percent Lower Risk of Symptom Development Has Demonstrated the First ALS Prevention Trial Success and the Biomarker-Monitored Presymptomatic Treatment Strategy That Genetic Testing Enables for At-Risk SOD1 Carriers.Biogen and Ionis Pharmaceuticals's tofersen in VALOR demonstrated 60% reduction in CSF neurofilament light chain, a biomarker of axonal injury, and 43% slowing of clinical decline in SOD1-ALS patients when given early enough to demonstrate functional benefit that was not the primary endpoint of the initial 28-week trial. The FDA's accelerated approval using NfL as a surrogate biomarker established the regulatory precedent for biomarker-based ALS approval that subsequent ALS gene-targeting programmes including C9orf72 and FUS-targeting ASOs are building upon. Biogen's commercial launch of Qalsody in SOD1-ALS creates the first precision medicine infrastructure in ALS , including genetic testing, patient registries, and neurologist awareness , that sets the template for future genotype-defined ALS treatment programmes.
Tofersen SOD1-Targeting ASO Silencing the Causative Mutation in Symptomatic SOD1 ALS and Preventing Symptom Onset in Presymptomatic Carriers Represents the Precision Medicine Template That Genotype-Specific ASO Therapy Provides for the Genetic ALS Subtypes.Amylyx Pharmaceuticals's AMX0035 demonstrated 2.32-point ALSFRS-R improvement over 24 weeks in CENTAUR versus placebo and survival benefit of 4.8 months in post-hoc analysis, earning FDA approval as the first ALS treatment approved in 5 years and the only drug other than riluzole and edaravone showing benefit in broad ALS. The combination addresses mitochondrial and endoplasmic reticulum stress pathways that represent downstream consequences of multiple ALS genetic and sporadic disease mechanisms, providing a rationale for benefit in unselected patients regardless of underlying causative mutation. Amylyx's voluntary withdrawal of AMX0035 after the PHOENIX confirmatory trial failed to replicate CENTAUR's functional benefit illustrates the high risk of ALS drug development where positive Phase 2 signals have historically failed to validate in larger Phase 3 programmes.
Relyvrio Phenylbutyrate-Taurursodiol Combination 25 Percent Slower ALSFRS-R Decline in CENTAUR Plus Accelerated Approval Pathway Followed by Voluntary Market Withdrawal When Phase III Confirmatory Trial Failed Illustrates the Accelerated Approval Pathway's Confirmatory Trial Requirement.The C9orf72 repeat expansion causing approximately 40% of familial ALS and 5-8% of sporadic ALS makes it the most common genetic cause of ALS and frontotemporal dementia, and multiple ASO programmes from Biogen-Ionis, Wave Life Sciences, and Neurimmune are in Phase 1-2 targeting repeat RNA foci and dipeptide repeat protein toxicity. The dual toxic gain-of-function from repeat RNA and dipeptide repeat proteins combined with loss of C9orf72 function creates therapeutic complexity requiring approaches that reduce toxic species without further reducing already-diminished C9orf72 protein levels. Mass spectrometry measurement of CSF dipeptide repeat proteins as pharmacodynamic biomarkers is enabling early-phase trials to confirm target engagement and select the most biologically active dose before committing to large Phase 3 programmes that have historically failed in ALS.
For related market intelligence, see the Neurology Drug Market.
8. Segmental Analysis
By drug class, the antioxidant and neuroprotective segment dominated the ALS Market in 2025, as Mitsubishi Tanabe Pharma's Radicava anchored treatment alongside generic riluzole across the diagnosed population, generating the largest share of ALS treatment revenue.
By genetic subtype, the SOD1 and familial segment is projected to register the highest growth rate through 2034, as Biogen and Ionis Pharmaceuticals's Qalsody antisense therapy targets specific genetic mutations and establishes precision approaches for the subset of ALS with identifiable causative variants.
9. Regional Analysis
Regional demand patterns across the ALS Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the ALS Market in 2025, accounting for approximately 44% of global revenue, attributed to US premium pricing for tofersen, riluzole, and edaravone and the concentration of Biogen and Mitsubishi Tanabe commercial operations. Moreover, tofersen prescribing in genetically confirmed SOD1-mutated ALS is most advanced in the US neurology setting. In addition, C9orf72 clinical development is centred in North American programmes. Regional dominance is due to this combination of pricing environment and precision genetic therapy launch.
Highest CAGR Region
Europe is projected to register the highest CAGR in the ALS Market through 2034, driven by expanding tofersen access across European healthcare systems and the large European ALS patient population with active genetic testing programmes identifying SOD1 and C9orf72 patients. The region is also witnessing C9orf72 clinical trial participation growing. Moreover, established riluzole prescribing sustains demand. The combination of these demand drivers and access expansion positions Europe for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The ALS Market was valued at USD 854.40 Mn in 2025 and is projected to reach USD 2,890.10 Mn by 2034, growing at a CAGR of 14.5% over the 2026–2034 forecast period.
The ALS Market is projected to grow at a CAGR of 14.5% from 2026 to 2034.
North America dominated the ALS Market in 2025, accounting for approximately 44% of global revenue, attributed to US premium pricing for tofersen, riluzole, and edaravone and the concentration of Biogen and Mitsubishi Tanabe commercial operations.
The leading companies in the ALS Market include Mitsubishi Tanabe Pharma, Biogen, Ionis Pharmaceuticals, Amylyx Pharmaceuticals, Sanofi, PTC Therapeutics, Denali Therapeutics, Cytokinetics, BrainStorm Cell Therapeutics.
Tofersen atlas presymptomatic sod1 als 55 percent lower risk of symptom development has demonstrated the first als prevention trial success and the biomarker-monitored presymptomatic treatment strategy that genetic testing enables for at-risk sod1 carriers.
By drug class, the antioxidant and neuroprotective segment dominated the ALS Market in 2025, as Mitsubishi Tanabe Pharma's Radicava anchored treatment alongside generic riluzole across the diagnosed population, generating the largest share of ALS treatment revenue.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.